Evaluating a new strategy for prophylaxis to prevent Pneumocystis carinii pneumonia in HIV-exposed infants in Thailand
Chokephaibulkit, Kulkanyaa; Chuachoowong, Ruttbc; Chotpitayasunondh, Taweed; Chearskul, Sanaya; Vanprapar, Niruna; Waranawat, Narisd; Mock, Philipc; Shaffer, Nathance; Simonds, R. J.*; for the Bangkok Collaborative Perinatal HIV Transmission Study Group
From the aDepartment of Pediatrics, and bDepartment of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; cThe HIV/AIDS Collaboration, Nonthaburi, Thailand; dQueen Sirikit National Institute of Child Health, Department of Medical Services, Ministry of Public Health, Bangkok, Thailand; and eDivision of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Received: 15 February 2000; accepted: 25 February 2000.
Correspondence and reprint requests to: Kulkanya Chokephaibulkit, MD, Division of Infectious Diseases, Department of Pediatrics, Siriraj Hospital, 2 Prannok Road., Bangkoknoi, Bangkok 10700, Thailand. Tel: +66 2 419 7027; fax: +66 2 718 4769; e-mail: firstname.lastname@example.org
*Members of the study group listed at the end of the paper.
Objective: To evaluate a strategy for prophylaxis against Pneumocystis carinii pneumonia (PCP) for infants in Thailand.
Methods: HIV-infected women were offered trimethoprim–sulfamethoxazole for PCP prophylaxis for their children at 1–2 months of age. When the children reached 6 months of age, investigators simulated a decision to continue or stop prophylaxis on the basis of clinical criteria, and compared their decisions with results of polymerase chain reaction (PCR) testing for HIV. We calculated the proportions of children who received and completed prophylaxis, and compared the rates of pneumonia and death from pneumonia with rates from an earlier prospective cohort.
Results: Of 395 eligible infants, 383 (97%) started prophylaxis. By 6 months of age, 10 (2.6%) were lost to follow-up, three (0.8%) were non-adherent, seven (2%) had stopped because of adverse events, four (1%) had died, and 359 (94%) still received prophylaxis. At 6 months of age, 30 (70%) of 43 HIV-infected children and 16 (5%) of 316 uninfected children met the clinical criteria to continue prophylaxis. The incidence of pneumonia at 1 to 6 months of age was 22% (15/68) in the earlier cohort, and 13% (6/46) in the recent cohort [relative risk (RR) 0.6, 95% confidence interval (CI) 0.3–1.4;P = 0.22]; mortality rates were 9% and 4%, respectively (RR 0.5; 95% CI 0.1–2.3;P = 0.47).
Conclusion: This PCP prophylaxis strategy appeared to be acceptable and safe, may have reduced morbidity and mortality from pneumonia, and should be considered in developing countries where early laboratory diagnosis of perinatal HIV infection is unavailable.
Pneumocystis carinii pneumonia (PCP) is the most common serious opportunistic infection among children infected with HIV in the United States . In Thailand, PCP was the cause of at least one third of the cases of severe pneumonia in HIV-infected children hospitalized at Siriraj Hospital, a large tertiary care hospital in Bangkok . Moreover, presumptively diagnosed PCP was the most common AIDS-defining condition reported for Thai children during 1988–1995 .
The US Centers for Disease Control and Prevention recommended in 1995 that trimethoprim–sulfamethoxazole (TMP–SMX) be offered as primary prophylaxis for PCP to all children born to HIV-infected women until HIV infection in the child can be reasonably excluded on the basis of virological tests such as polymerase chain reaction (PCR) . This recommendation followed from observations that the incidence of PCP in infants peaks at age 2–6 months, when the HIV infection status of many children is still unknown, the risk of mortality from PCP is high, and the prognosis after PCP is poor [1,4]. Moreover, unlike in adults and older children, PCP may develop in HIV-infected infants who have relatively high CD4 lymphocyte counts, making such counts unreliable as risk markers [5–7].
This recommendation has not been adopted widely in Thailand or other developing countries for several reasons. There is concern that the risk of adverse events may outweigh the benefits, resistance to TMP–SMX could become widespread and diminish its effectiveness in treating common childhood infections, and the cost of universal prophylaxis may be too great. Moreover, the risk : benefit ratio will increase as more children born to HIV-infected women escape HIV infection (and the risk of PCP) because of the increasing use of zidovudine to prevent mother–infant HIV transmission . In addition, because PCR and other tests to diagnose perinatal HIV infection in infancy are not generally available, determining that a child is not infected with HIV requires waiting until the second year of life, when HIV antibody testing is reliable. The time necessary to exclude HIV infection may thus be several times longer than in settings in which PCR testing is available, thereby increasing the costs and the risks of using TMP–SMX for uninfected children who are not at risk of PCP.
The experience at Siriraj Hospital, similar to that in centres in other countries, is that children whose first symptom of HIV infection is PCP are generally younger than 6 months of age . We therefore proposed a strategy for primary PCP prophylaxis, by which all children born to HIV-infected mothers start receiving prophylaxis at 1–2 months of age, and the presence or absence of HIV-related signs or symptoms is used to determine whether to continue or stop prophylaxis at 6 months of age. In this paper, we evaluate the feasibility of this strategy and estimate its impact on preventing pneumonia in HIV-infected children between 1 and 6 months of age.
The evaluation was conducted prospectively at two referral hospitals in Bangkok: Queen Sirikit National Institute for Child Health and Siriraj Hospital, where an estimated one third of HIV-infected children in Bangkok receive care. All infants born to HIV-infected mothers enrolled in a phase III randomized trial of short-course antenatal zidovudine to reduce mother–infant HIV transmission from May 1996 to December 1997 were included in this evaluation . For the trial, infants were seen at 1, 2, 4, 6, 9, 12, and 18 months of age for immunizations and routine child care. HIV–PCR testing was done at birth and at 2 and 6 months of age. HIV-infected women were counselled to avoid breastfeeding and were provided infant formula.
All women were offered TMP–SMX (150 mg of TMP/M2/day in two divided doses three times a week) for their infants at the 1 or 2 month visit, depending on the hospital and the timing of the child's visit, after counselling (Fig. 1). Adherence to prophylaxis (based on self-report and record of medication refills), adverse reactions, HIV-related signs and symptoms, illnesses, and hospitalizations were recorded at each visit as part of routine care. To simulate general practice at these hospitals and in Thailand, in which PCR and other early diagnostic tests are usually not available, PCR results for the infants remained masked until the 6 month visit. At the 6 month visit, each child was evaluated by a physician investigator on clinical criteria and the investigator simulated a decision to continue or stop prophylaxis (Fig. 1). After this decision was recorded, the PCR results were unmasked and the decision could be changed on the basis of these results or the later development of HIV-associated symptoms. If a child had symptoms of HIV infection before 6 months of age and there was a need to know the child's HIV status for clinical management, the investigator would unmask the PCR result after categorizing the child as being symptomatic.
HIV antibody and CD4 T lymphocyte count tests were performed when the children were 12 months old. The decision to continue prophylaxis after this age was based on HIV status, clinical status, and CD4 T lymphocyte count. In general, PCP prophylaxis was continued for children classified as immunological category 3 or clinical category C in the Centers for Disease Control and Prevention classification system .
Outcome measurement and statistical analysis
We measured rates of acceptance of prophylaxis by mothers and completion of PCP prophylaxis until 6 months of age by children. We determined the number of children who stopped taking TMP–SMX because of poor adherence or neutropenia, thrombocytopenia, anaemia, haemolysis, rash, or other reasons. For this analysis, a child was considered to be infected if at least one specimen tested positive by PCR, and a child was considered uninfected if the specimen at 6 months of age tested negative by PCR. The simulated decision about prophylaxis, based on clinical criteria (Fig. 1), was compared with the child's infection status, based on PCR results. In addition, each clinical criterion was evaluated for correlation with HIV infection status. The incidences of pneumonia and deaths from pneumonia between 1 and 6 months of age in this population were compared with those in a prospective study in the same hospitals in 1992–1994, when primary PCP prophylaxis was not used . In both studies, pneumonia was usually diagnosed on the basis of clinical examination and chest X-ray. We performed comparative analyses by using chi square and Fisher's exact tests. All P values are two-tailed.
All 395 infants born in this cohort were included in the evaluation (Fig. 2). TMP–SMX prophylaxis was offered for 383 infants. After prophylaxis was begun, 10 (2.6%) children were lost to follow-up before 6 months of age, and three (0.8%) did not take the medication regularly. Seven (1.8%) children, three of whom were HIV infected, stopped prophylaxis before 6 months of age because of adverse events (five with mild rashes, one each with oral ulcers, mild anaemia); all improved promptly after prophylaxis was stopped and all were still free of illness at 12 months of age. Of the four (1%) infants who received prophylaxis and died before 6 months of age, three were HIV infected. None had symptoms suggesting a reaction to TMP–SMX.
Clinical decisions about prophylaxis at 6 months
Of the 359 children who continued prophylaxis until their 6 month visit, 313 (87.2%) [13 (4.2%) HIV infected] remained asymptomatic (Table 1). One or more signs or symptoms associated with HIV infection developed in 46 (12.8%) children [16 (34.8%) not infected]. On the basis of clinical criteria, 30 (70%) of 43 HIV-infected children, but only 16 (5%) of 316 HIV-uninfected children, would have continued prophylaxis after 6 months of age. The positive and negative predictive values of the clinical criteria for predicting the child's infection status were 65 and 96%, respectively. If individual clinical criteria alone were used to make the decision about prophylaxis at 6 months of age, using the presence of splenomegaly or hepatomegaly would have led to the most ‘correct’ decisions (Table 2).
Five of the 13 infected children who were asymptomatic at 6 months of age continued to receive prophylaxis on the basis of PCR test results (three children) or restarted prophylaxis before 9 months of age because symptoms had developed (two children). Pneumonia did not develop in any of the 13 children before 12 months of age, although two of the eight who did not continue prophylaxis died, one of Enterobacter cloacae sepsis and one of diarrhoea with shock. All 16 uninfected children with symptoms suggestive of HIV infection stopped prophylaxis after the PCR results were known. There were no problems with TMP–SMX prophylaxis among the 35 HIV-infected children who continued to receive it between 6 and 12 months of age.
Benefit of prophylaxis strategy
Pneumonia developed at between 1 and 6 months of age in six (13%) of the 46 HIV-infected children who received prophylaxis; two of these children died (one at 6 months of age of suspected pneumonia, at a local hospital). The causes of these pneumonias were not determined.
Among the 68 HIV-infected children in the 1992–1994 cohort, the incidence of pneumonia between ages 1 and 6 months was 15 out of 68 (22.1%) , compared with six out of 46 (13.0%) in the recent cohort [relative risk (RR) 0.59, 95% confidence interval (CI) 0.25–1.41, P = 0.22]. The mortality rate from pneumonia between the ages of 1 and 6 months in the previous cohort was six out of 68 (8.8%), compared with two out of 46 (4.3%) in the recent cohort (RR 0.49, 95% CI 0.10–2.34, P = 0.47).
PCP is an important opportunistic infection in HIV-infected children, especially young infants, and is a common cause of death. In Europe and the United States, PCP develops in 12–25% of HIV-infected children during their first year of life [1,5,11], and the reported median survival of children after an episode of PCP is only 19 months or less [1,12]. Because P. carinii seems to be a ubiquitous organism to which all children are exposed, prophylaxis is the most effective way to prevent PCP among those at risk of disease . The use of PCP prophylaxis prolongs time to category C for HIV-infected children , decreases the risk of the early death of infants , and prolongs the survival of HIV-infected adults . In young infants, however, PCP may develop despite relatively normal CD4 T lymphocyte counts and the absence of symptoms [1,5–7,16], thereby reducing the effectiveness of using clinical or immunological risk markers to guide prophylaxis, a strategy that is effective for older children and adults. This finding led to the 1995 recommendation in the United States to prescribe prophylaxis for all HIV-infected infants in the first year of life . In addition, because PCP may occur before a child's HIV infection status has been determined, these guidelines recommend prophylaxis for all HIV-exposed children until infection can be excluded, even though fewer than 20% of children who receive prophylaxis are HIV infected and are thus at potential risk of PCP.
In Thailand, despite the fact that approximately three times as many children are born to HIV-infected women each year (approximately 15 000) as in the United States (approximately 6000), this approach to primary PCP prophylaxis has not been generally adopted. This is partly because of the unavailability of diagnostic tests to guide decisions about stopping prophylaxis for infants who are not at risk of PCP because they are not HIV infected. The usual practice in hospitals in Thailand is to wait for symptoms of HIV infection to appear before starting prophylaxis. As a result, prophylaxis is not started for many young HIV-infected infants at risk of PCP. To improve PCP prevention in this population, we evaluated a strategy of universal PCP prophylaxis for all HIV-exposed infants during the age of highest risk – 2–6 months of age. Instead of using laboratory tests for HIV infection to guide the decision to stop or continue prophylaxis, we used the presence or absence of HIV-associated clinical findings when the child reached 6 months of age, a strategy that could be useful for Thailand and other developing countries.
On the basis of our evaluation, this strategy seemed acceptable, safe, and helpful in making decisions about prophylaxis. All 383 mothers who were offered prophylaxis agreed, and only 3% adhered poorly to clinic visits or medication. Only 2% of children had to stop prophylaxis because of adverse events, all of which were mild and reversible. In addition, although our ability to determine the efficacy of this strategy was limited and our findings were not statistically significant, the data seem promising. Compared with the incidence in a historical control group, the incidence of pneumonia before 6 months of age was lower by nine cases per 100 HIV-infected children, and mortality as a result of pneumonia was lower by four deaths per 100 HIV-infected children. If this finding represents an actual reduction of pneumonia, it corroborates the findings in one of our hospitals that the incidence of severe pneumonia among HIV-infected children declined after a universal PCP prophylaxis strategy was instituted .
Making a clinical decision for children at 6 months of age seems to be an effective tool for continuing prophylaxis for infected children, while excluding low-risk infants from the prolonged use of TMP–SMX. Basing the decision on the presence or absence of one of several clinical findings would have resulted in continuing prophylaxis for most (70%) of the infected children after 6 months of age. Using only the presence of splenomegaly would have resulted in accurate decisions about prophylaxis for 94% of children overall.
Our evaluation had several limitations. We did not examine the effect of this strategy on the development of drug resistance in bacteria or other organisms that cause infections in the population. We also did not examine its cost-effectiveness or effect on the quality of life. We did not have a contemporaneous, randomized control group with which to compare the incidence of pneumonia and death; factors other than PCP prophylaxis may have contributed to the apparent decline in these rates. Moreover, our sample size did not have the statistical power to differentiate effectiveness from chance variation. Finally, the correlation of clinical symptoms with HIV infection status we observed may differ in other populations, and we did not evaluate the ability of providers other than paediatricians to diagnose findings such as splenomegaly.
Nonetheless, the favourable findings may have implications for the care of HIV-exposed children in Thailand and other countries where diagnostic testing and treatment resources are limited. In particular, as more developing countries follow Thailand's lead in implementing perinatal HIV prevention programmes that include routine voluntary HIV counselling and testing during pregnancy [17,18], increasing numbers of HIV-exposed children will be identified and will require care from birth. PCP prophylaxis has become integral to the care of HIV-exposed children in the United States and other countries with substantial healthcare resources. Whether providing PCP prophylaxis for all HIV-exposed children will be adopted in countries with more limited resources will require weighing the probable reduction in morbidity and mortality against the cost (approximately US$3 per treatment to 6 months of age), other potential negative outcomes, such as the development of drug resistance, and the potential decline in the perinatal HIV transmission rate resulting from the introduction of effective interventions. In addition, this approach needs to be evaluated in other settings, especially where other causes of splenomegaly (e.g. thalassaemia, malaria) and other findings may be prevalent and where care is provided by less experienced healthcare workers.
The authors gratefully acknowledge the dedicated field work of the project study nurses and social workers: K. Neeyapun, B. Jetsawang (team leaders); S. Bhengsri, S. Henchaichon, S. Jalanchavanapate, K. Klumthanom, R. Krajangthong, C. Prasert, W. Sanyanusin, W. Suwannapha, S. Sorapipatana, S. Suwanmaitre, W. Triphanitchkul, and C. Yuvasevee. The authors would also like to thank Tim Mastro, Eve Lackritz, Martha Rogers, and Marie Morgan for critical review of the manuscript.
1. Simonds RJ, Oxtoby MJ, Caldwell MB, Gwinn ML, Rogers MF. Pneumocystis cariniipneumonia among US children with perinatally acquired HIV infection. JAMA 1993, 270: 470 –473.
2. Chokephaibulkit K, Wanachiwanawin D, Chearskul S. et al. Pneumocystis cariniisevere pneumonia among human immunodeficiency virus-infected children in Thailand: the effect of a primary prophylaxis strategy. Pediatr Infect Dis J 1999, 18: 147 –152.
3. Ministry of Public Health, Thailand. Pediatric AIDS, Thailand. Wkly Epidemiol Surveillance Rep 1996, 27: 501 –515.
4. Centers for Disease Control and Prevention. 1995 Revised guidelines for prophylaxis againstPneumocystis cariniipneumonia for children infected with or perinatally exposed to human immunodeficiency virus. MMWR 1995, 44: 1 –11.
5. European Collaborative Study Group. CD4 T cell count as predictor ofPneumocystis cariniipneumonia in children born to mothers infected with HIV. BMJ 1994, 308: 437 –440.
6. Simonds RJ, Lindegren ML, Thomas P. et al. Prophylaxis againstPneumocystis cariniipneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. N Engl J Med 1995, 332: 786 –790.
7. Kovacs A, Frederick T, Church J, Eller A, Oxtoby M, Mascola L. CD4 T-lymphocyte counts andPneumocystis cariniipneumonia in pediatric HIV infection. JAMA 1991, 265: 1698 –1703.
8. Shaffer N, Chuachoowong R, Mock PA. et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet 1999, 353: 773 –780.
9. Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994, 43: 1 –10.
10. Chokephaibulkit K, Chotpitayasunondh T, Shaffer N, et al. Clinical outcome and survival associated with perinatal HIV-1 subtype E infection, Bangkok, Thailand.XIIth International Conference on AIDS. Geneva, June 1998 [abstract 13366].
11. Thea DM, Lambert G, Weedon J. et al. Benefit of primary prophylaxis before 18 months of age in reducing the incidence ofPneumocystis cariniipneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants. Pediatrics 1996, 97: 59 –64.
12. Scott GB, Hutto C, Makuch RW. et al. Survival in children with perinatally acquired human immunodeficiency virus type 1 infection. N Engl J Med 1989, 321: 1791 –1796.
13. Simonds RJ, Hughes WT, Feinberg J, Navin TR. PreventingPneumocystis cariniipneumonia in persons infected with human immunodeficiency virus. Clin Infect Dis 1995, 21 (Suppl. 1) : S44 –48.
14. Maldonado YA, Araneta RJ, Hersh AL. et al. Pneumocystis cariniipneumonia prophylaxis and early clinical manifestations of severe perinatal human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 1998, 17: 398 –402.
15. Osmond D, Charlebois E, Lang W, Shiboski S, Moss A. Change in AIDS survival time in two San Francisco cohorts of homosexual men, 1983 to 1993. JAMA 1994, 271: 1083 –1087.
16. Chearskul S, Wanprapa N, Boonyavit W. A study of vertically acquired human immunodeficiency virus-1 infection at Siriraj Hospital during 1990–1993. Siriraj Hosp Gaz 1995, 47 (Suppl. 3) : 98 –103.
17. Thaineua V, Sirinirund P, Tanbanjong A, Lallemant M, Soucat A, Lamboray JL. From research to practice: use of short course zidovudine to prevent mother-to-child HIV transmission in the context of routine health care in northern Thailand. Southeast Asian J Trop Med Public Health 1998, 29: 429 –442.
18. Kanshana S, Thewanda D, Teeraratkul A, et al. Implementing short-course zidovudine to reduce mother-infant HIV transmission in a large regional pilot program in northeastern Thailand AIDS, in press.
Other members of the Bangkok Collaborative Perinatal HIV Transmission Study Group
Faculty of Medicine, Siriraj Hospital, Department of Obstetrics and Gynaecology: S. Neungton, P. Chaisilwattana, A. Roongpisuthipong, A. Chalermchokcharoenkit, K. Sirimai, P. Phopong, C. Bhadrakom, P. Chaiyakul, P. Rattananikhom, R. Prechanont
Faculty of Medicine, Siriraj Hospital, Department of Pediatrics: M. Tuchinda, S. Pichitchaichan, W. Boonyavit
Faculty of Medicine, Siriraj Hospital, Department of Microbiology: C. Wasi
Rajavithi Hospital, Department of Obstetrics and Gynaecology: P. Chinayon, W. Siriwasin, S. Asavapiriyanont, B. In-neam, S. Supatosa, C. Kannasot, S. Sangkasuwan, S. Leampojara, P. Pramukhakul
Rajavithi Hospital, Laboratory: S. Singhanati, G. Kaewchaiyo
Rajavithi Hospital, Department of Nursing: J. Sawakwan, N. Montasewee
Queen Sirikit National Institute for Child Health: S. Horpaopan, V. Sangtaweesin, P. Na Chiengmai, R. Kulvisuthpravit, B. Phasukdee, P. Sojirat
The HIV/AIDS Collaboration: T.D. Mastro, K. Limpakarnjanarat, W. Supapol, A. Bennetts, N. Chantharojwong, T. Naiwatanakul, J. Laosakkitiboran, P. Yuentrakul, C. Manopaiboon
HIV; infants; Pneumocystis carinii pneumonia; pneumonia; prophylaxis
© 2000 Lippincott Williams & Wilkins, Inc.
Highlight selected keywords in the article text.